1	
2	
3	
4	
5	
6	LUMI-CELL® ER ASSAY
7	ANTAGONIST PROTOCOL
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	National Toxicology Program (NTP) Interagency Center for the Evaluation of Alternative
19	Toxicological Methods (NICEATM)
20	
21	Developed by:
22	Xenobiotic Detection Systems, Inc.
23	1601 E. Geer St., Suite S
24	Durham, NC 2770413
25	12 March 2009

26			TABLE OF CONTENTS	
27	LIST OF ACRONYMS AND ABBREVIATIONS vi			
28	LIST	LIST OF FIGURESviii		
29	LIST	OF TA	ABLESix	
30	1.0	Purp	ose1	
31	2.0	Spon	sor1	
32		2.1	Substance Inventory and Distribution Management3	
33	3.0	Defin	nitions3	
34	4.0	Testi	ng Facility and Key Personnel4	
35		4.1	Testing Facility4	
36		4.2	Key Personnel4	
37	5.0	Ident	tification of Test and Control Substances4	
38		5.1	Test Substances4	
39		5.2	Controls4	
40	6.0	Over	view of General Procedures For Antagonist Testing5	
41		6.1	Range Finder Testing6	
42		6.2	Comprehensive Testing	
43	7.0	Mate	rials for LUMI-CELL® ER Antagonist Testing7	
14		7.1	BG1Luc4E2 Cells	
45		7.2	Technical Equipment8	
46		7.3	Reference Standard, Controls, and Tissue Culture Supplies9	
17	8.0	Prep	aration of Tissue Culture Media and Solutions11	
48		8.1	RPMI 1640 Growth Medium (RPMI)11	
19		8.2	Estrogen-Free DMEM	

50		8.3	1X Trypsin Solution	12
51		8.4	1X Lysis Solution	12
52		8.5	Reconstituted Luciferase Reagent	12
53	9.0	Over	view of Propagation and Experimental Plating of	
54		BG1I	Luc4E2 Cells	13
55		9.1	Procedures for Thawing Cells and Establishing Tissue Cultures	13
56			9.1.1 Thawing Cells	13
57			9.1.2 Establishing Tissue Cultures	14
58		9.2	Ongoing Tissue Culture Maintenance, Conditioning in Estrogen-free	
59			Medium, and Plating Cells for Experimentation	16
60			9.2.1 Ongoing Tissue Culture Maintenance	17
61			9.2.2 Conditioning in Estrogen-free Medium	18
62			9.2.3 Plating Cells Grown in Estrogen-free DMEM for	
63			Experimentation	18
64	10.0	Prepa	aration of Test Substances	21
65		10.1	Determination of Test Substance Solubility	21
66	11.0	Prepa	aration of Reference Standard, Control, and Test Substance	
67		Stock	Solutions for Range Finder and Comprehensive Testing	22
68		11.1	Preparation of Ral/E2 Stock Solutions	22
69			11.1.1 E2 Stock Solution	22
70			11.1.2 Raloxifene Stock Solution	23
71		11.2	Ral/E2 Range Finder Testing Stock	23
72			11.2.1 Raloxifene Dilutions	23
73			11.2.2 Preparation of Ral/E2 Range Finder Working Stocks	23
74		11.3	Ral/E2 Comprehensive Testing Stock	24

75			11.3.1 Raloxifene Dilutions	24
76			11.3.2 Preparation of Ral/E2 Comprehensive Testing Working	
77			Stocks	25
78		11.4	Flavone/E2 Stock Solution	25
79	12.0	Prepa	aration of Reference Standard, Control, and Test Substance	
80		Dosin	ng Solutions for Range Finder and Comprehensive Testing	26
81		12.1	Preparation of Reference Standard and Control Dosing Solutions	
82			for Range Finder Testing	26
83			12.1.1 Preparation of Ral/E2 Reference Standard Range Finder	
84			Dosing Solutions	26
85			12.1.2 Preparation of DMSO Control Range Finder Dosing	
86			Solution	26
87			12.1.3 Preparation of E2 Control Range Finder Dosing	
88			Solution	26
89		12.2	Preparation of Test Substance Dosing Solutions for Range	
90			Finder Testing	27
91		12.3	Preparation of Reference Standard and Control Dosing	
92			Solutions for Comprehensive Testing	28
93			12.3.1 Preparation of Ral/E2 Reference Standard Dosing	
94			Solutions for Comprehensive Testing	29
95			12.3.2 Preparation of DMSO Control Comprehensive	
96			Testing Dosing Solution	29
97			12.3.3 Preparation of E2 Control Comprehensive Testing	
98			Dosing Solution	29
99			12.3.4 Preparation of Flavone/E2 Control Comprehensive	
100			Testing Dosing Solution	29
101				

101		12.4	Preparation of Test Substance Dosing Solutions for	•
102			Comprehensive Testing	30
103			12.4.1 Preparation of Test Substance 1:2 Dilution for	•
104			Comprehensive Testing	30
105			12.4.2 Preparation of Test Substance 1:5 Dilution for	2.1
106			Comprehensive Testing	
107	13.0	Gene	ral Procedures for the Testing of Coded Substances	32
108		13.1	Application of Reference Standard, Control, and Test Substances	32
109			13.1.1 Preparation of Excel® Data Analysis Template for	
110			Range Finder Testing	33
111			13.1.2 Preparation of Excel® Data Analysis Template for	
112			Comprehensive Testing	34
113		13.2	Visual Evaluation of Cell Viability	35
114		13.3	Lysis of Cells for LUMI-CELL® ER	36
115		13.4	Measurement of Luminescence	36
116		13.5	Data Analysis	36
117			13.5.1 Collection and Adjustment of Luminometer Data for Range	
118			Finder Testing	37
119			13.5.2 Collection and Adjustment of Luminometer Data for	
120			Comprehensive Testing	39
121			13.5.3 Determination of Outliers	41
122			13.5.4 Acceptance Criteria	42
123			13.5.4.1 Range Finder Testing	42
124			13.5.4.2 Comprehensive Testing	42
125	14.0	Rang	e Finder Testing	43
126	15.0	Com	prehensive Testing	49

127	16.0	Comp	pilation of the Historical Quality Control Database	51
128		16.1	E2 Control	52
129		16.2	DMSO Control	52
130	17.0	Quali	ity Testing of Materials	52
131		17.1	Tissue Culture Media	53
132		17.2	G418	54
133		17.3	DMSO	54
134		17.4	Plastic Tissue Culture Materials	55
135	18.0	Refer	rences	56
136				
137				

137	LIST OF AC	RONYMS AND ABBREVIATIONS
138	13 mm test tube	13 x 100 mm glass test tubes
139	DMEM	Dulbecco's Modification of Eagle's Medium
140	DMSO	Dimethyl Sulfoxide
141	DMSO Control	1% v/v dilution of DMSO in tissue culture media
142		used as a vehicle control
143	E2	17β-estradiol
144	E2 Control	$2.5 \times 10^{-5} \mu g/mL$ E2 used as a control.
145	IC ₅₀ Value	Concentration that produces a half-maximal response as
146		calculated using the four parameter Hill function.
147	ER	Estrogen Receptor
148	Estrogen-free DMEM	DMEM (phenol red free), supplemented with 1 %
149		Penicillin/Streptomycin, 2 % L-Glutamine, and 5%
150		Charcoal-dextran treated FBS
151	FBS	Fetal Bovine Serum
152	Flavone/E2 Control	$25 \mu g/mL \text{ flavone} + 2.5 \times 10^{-5} \mu g/mL \text{ E2},$
153		used as a weak positive control.
154	G418	Gentamycin
155	Ral/E2 Reference Standard	Nine point dilution of raloxifene HCl + $2.5 \times 10^{-5} 17\beta$ -
156		estradiol reference standard for the LUMI-CELL® ER
157		antagonist assay
158	RPMI	RPMI 1640 growth medium
159	TA	Transcriptional Activation

160	T25	25 cm ² tissue culture flask
161	T75	75 cm ² tissue culture flask
162	T150	150 cm ² tissue culture flask
163		

163		LIST OF FIGURES	
164	Figure 7-1	pGudLuc7.ERE Plasmid	7
165	Figure 9-1	Hemocytometer Counting Grid	19
166	Figure 14-1	Antagonist Range Finder Test Plate Layout	44
167	Figure 14-2	Antagonist Range Finder (example 1)	46
168	Figure 14-3	Antagonist Range Finder (example 2)	47
169	Figure 14-4	Antagonist Range Finder (example 3)	47
170	Figure 14-5	Antagonist Range Finder (example 4)	48
171	Figure 14-6	Antagonist Range Finder (example 5)	48
172	Figure 15-1	Antagonist Comprehensive Test Plate Layout	50
173			

173		LIST OF TABLES	
174	Table 6-1	Concentration of Ral/E2 Reference Standard Used for	
175		Comprehensive Testing	5
176	Table 11-1	Preparation of E2 Stock Solution	22
177	Table 11-2	Preparation of Raloxifene Stock Solution	23
178	Table 11-3	Preparation of Raloxifene Dilutions for Range Finder Testing	23
179 180	Table 11-4	Concentrations of Raloxifene and E2 in the Ral/E2 Range Finder Working Stocks	24
181	Table 11-5	Preparation of Raloxifene Dilutions for Comprehensive Testing	24
182 183	Table 11-6	Concentrations of Raloxifene and E2 in the Ral/E2 Working Stock	25
184 185	Table 12-1	Preparation of Test Substance Serial Dilution for Range Finder Testing	27
186 187	Table 12-2	Addition of E2 to Test Substance Serial Dilution for Range Testing	27
188 189	Table 12-3	Preparation of Ral/E2 Reference Standard Dosing Solution for Comprehensive Testing	29
190 191	Table 12-4	Preparation of Test Substance 1:2 Dilutions for Comprehensive Testing	31
192 193	Table 12-5	Preparation of Test Substance 1:5 Dilutions for Comprehensive Testing	32
194	Table 13-1	Visual Observation Scoring	36
195	Table 13-2	Q Test Values	42
106			

197	1.0	PURPOSE
198	This pr	otocol is designed to evaluate coded test substances for potential estrogen receptor (ER)
199	antagor	nist activity using the LUMI-CELL® ER assay.
200	2.0	SPONSOR
201	The Na	tional Toxicology Program (NTP) Interagency Center for the Evaluation of Alternative
202	Toxico	logical Methods (NICEATM), P.O. Box 12233 Research Triangle Park, NC 27709
203	Willian	n S. Stokes, DVM, DACLAM
204	Rear A	dmiral, U.S. Public Health Service
205	Chief V	Veterinary Officer, USPHS
206	Directo	or, NICEATM
207	Nationa	al Institute of Environmental Health Sciences, NIH, DHHS
208	Bldg. 4	401, Room 3129, MD EC-14
209	79 T.W	7. Alexander Drive
210	Researc	ch Triangle Park, NC 27709
211	Phone:	919-541-7997
212	Fax: 91	9-541-0947
213	Email:	stokes@niehs.nih.gov
214		
215	Raymo	nd Tice, Ph.D.
216	Deputy	Director, NICEATM
217	Nationa	al Institute of Environmental Health Sciences
218	MD EC	C-17, P.O. Box 12233
219	Researc	ch Triangle Park, NC 27709
220	Phone:	919-541-4482
221	FAX: 9	019-541-0947
222	Email:	tice@niehs.nih.gov
223		

- David Allen, Ph.D.
- 225 Principal Investigator
- 226 ILS, Inc./Contractor supporting NICEATM
- National Institute of Environmental Health Sciences
- 228 MD EC-17, P.O. Box 12233
- 229 Research Triangle Park, NC 27709
- 230 Phone: 919-316-4587
- 231 FAX: 919-541-0947
- Email: allen7@niehs.nih.gov

- Frank Deal, M.S.
- 235 Staff Toxicologist
- 236 ILS, Inc./Contractor supporting NICEATM
- National Institute of Environmental Health Sciences
- 238 MD EC-17, P.O. Box 12233
- 239 Research Triangle Park, NC 27709
- 240 Phone: 919-316-4587
- 241 FAX: 919-541-0947
- Email: dealf@niehs.nih.gov

243

- 244 Patricia Ceger, M.S.
- 245 Project Coordinator/Technical Writer
- 246 ILS, Inc./Contractor supporting NICEATM
- National Institute of Environmental Health Sciences
- 248 MD EC-17, P.O. Box 12233
- 249 Research Triangle Park, NC 27709
- 250 Phone: 919-316-4556
- 251 Fax: 919-541-0947
- 252 E-Mail: <u>cegerp@niehs.nih.gov</u>

253

254	2.1	Substance Inventory and Distribution Management		
255	Cynthia	Smith, Ph.D.		
256	Chemistr	Chemistry Resources Group Leader		
257	National	Institute of Environmental Health Sciences		
258	MD EC-	06, P.O. Box 12233		
259	Research	Triangle Park, NC 27709		
260 261	Phone: 9	19-541-3473		
262	3.0	DEFINITIONS		
263		• Dosing Solution: The test substance, control substance, or reference standard		
264		solution which is to be placed into the tissue culture wells for experimentation.		
265		• Raw Data: Raw data includes information that has been collected but not		
266		formatted or analyzed, and consists of the following:		
267		 Data recorded in the Study Notebook 		
268		o Computer printout of initial luminometer data		
269		Other data collected as part of GLP compliance, e.g.:		
270		 Equipment logs and calibration records 		
271		 Test substance and tissue culture media preparation logs 		
272		 Cryogenic freezer inventory logs 		
273		• Soluble: Test substance exists in a clear solution without visible cloudiness or		
274		precipitate.		
275		• Study Notebook: The study notebook contains recordings of all activities related		
276		to the conduct of the LUMI-CELL® ER TA antagonist assay.		
277		• Test Substances: Substances supplied to the testing laboratories that are coded		
278		and distributed such that only the Project Officer, Study Management Team		
279		(SMT), and the Substance Inventory and Distribution Management have		
280		knowledge of their true identity. The test substances will be purchased, aliquoted,		

281		coded, and distributed by the Supplier under the guidance of the NIEHS/NTP
282		Project Officer and the SMT.
283	4.0	TESTING FACILITY AND KEY PERSONNEL ¹
284	4.1	Testing Facility
285	Xenobio	otic Detection Systems, Inc. (XDS), 1601 E. Geer St., Durham, NC 27704
286	4.2	Key Personnel
287		• Study Director: John Gordon, Ph.D.
288		• Quality Assurance Director: Mr. Carlos Daniel
289	5.0	IDENTIFICATION OF TEST AND CONTROL SUBSTANCES
290	5.1	Test Substances
291	Test sub	ostances are coded and will be provided to participating laboratories by the Substance
292	Invento	ry and Distribution Management team.
293	5.2	Controls
294	Control	s for the ER antagonist protocol are as follows:
295	Vehicle	control (dimethyl sulfoxide [DMSO]): 1% v/v dilution of DMSO (CASRN 67-68-5)
296	diluted	in tissue culture media.
297	Ral/E2	reference standard for range finder testing: Three concentrations (1.56 x 10 ⁻³ ,
298	3.91 x 1	0^{-4} , and 9.77 x 10^{-5} µg/mL) of raloxifene HCl (Ral), CASRN 84449-90-1, plus a fixed
299	concent	ration (2.5 x 10^{-5} µg/mL) of 17 β -estradiol (E2), CASRN: 50-28-2, in duplicate wells.
300	Ral/E2	reference standard for comprehensive testing: A serial dilution of Ral plus a fixed
301	concent	ration (2.5 x 10^{-5} µg/mL) of E2 consisting of nine concentrations of Ral/E2 in duplicate
302	wells.	

¹ Testing facility and personnel information are provided as an example.

303 *E2 control*: 17β -estradiol, 2.5 x 10^{-5} µg/mL E2 in tissue culture media used as a base line 304 negative control.

Flavone/E2 Control: Flavone, CASRN 525-82-6, 25 μg/mL, with 2.5 x 10⁻⁵ μg/mL E2 in tissue culture media used as a weak positive control.

6.0 OVERVIEW OF GENERAL PROCEDURES FOR ANTAGONIST TESTING

All experimental procedures are to be carried out under aseptic conditions and all solutions, glassware, plastic ware, pipettes, etc., shall be sterile. All methods and procedures shall be

documented in the study notebook.

305

306

307

313

315

319

320

322

311 Antagonist range finder testing is conducted on 96-well plates using three concentrations of

312 Ral/E2 (1.56 x 10^{-3} , 3.91 x 10^{-4} , and 9.77 x 10^{-5} µg/mL Ral) with 2.50 x 10^{-5} µg/mL E2) in

duplicate as the reference standard, with three replicate wells for the E2 and DMSO controls.

Comprehensive testing is conducted on 96-well plates using nine concentrations of Ral/E2 in

duplicate as the reference standard (**Table 6-1**). Four replicate wells for the DMSO control,

Flavone/E2 and E2 controls are included on each plate.

Table 6-1 Concentrations of Ral/E2 Reference Standard Used for Comprehensive Testing

Raloxifene Concentrations ¹	E2 Concentrations
1.25 x 10 ⁻²	2.5 x 10 ⁻⁵
6.25 x 10 ⁻³	2.5 x 10 ⁻⁵
3.13 x 10 ⁻³	2.5 x 10 ⁻⁵
1.56 x 10 ⁻³	2.5 x 10 ⁻⁵
7.81 x 10 ⁻⁴	2.5 x 10 ⁻⁵
3.91 x 10 ⁻⁴	2.5 x 10 ⁻⁵
1.95 x 10 ⁻⁴	2.5 x 10 ⁻⁵
9.77 x 10 ⁻⁵	2.5 x 10 ⁻⁵
4.88 x 10 ⁻⁵	2.5 x 10 ⁻⁵

¹Concentrations are presented in μg/mL.

Visual observations for cell viability are conducted for all experimental plates just prior to

LUMI-CELL® ER evaluation, as outlined in **Section 11.4**.

- Luminescence data, measured in relative light units (RLUs), is corrected for background luminescence by subtracting the mean RLU value of the vehicle control (DMSO) wells from the RLU measurements for each of the other wells of the 96-well plate. Data is then transferred into Excel® data management spreadsheets and GraphPad PRISM® 4.0 statistical software, graphed, and evaluated for a positive or negative response as follows:
 - A response is considered positive for antagonist activity when the average adjusted RLU for a given concentration is less than the mean RLU value minus three times the standard deviation for the E2 control.
 - Any luminescence at or above this threshold is considered a negative response.
- For substances that are positive at one or more concentrations, the concentration of test substance that causes a half-maximal response (the relative IC₅₀) is calculated using a Hill function analysis. The Hill function is a four-parameter logistic mathematical model relating the substance concentration to the response (typically following a sigmoidal curve) using the equation below

337
$$Y = Bottom + \frac{Top - Bottom}{1 + 10^{(logIC50-X)HillSlope}}$$

329

330

331

343

344

345

346

347

348

where Y = response (i.e., relative light units); X = the logarithm of concentration; Bottom = the minimum response; Top = the maximum response; log IC₅₀ = the logarithm of X as the response midway between Top and Bottom; and HillSlope describes the steepness of the curve. The model calculates the best fit for the Top, Bottom, HillSlope, and IC₅₀ parameters. See **Section 13.6.5** for more details.

Acceptance or rejection of a test is based on evaluation of reference standard and control results from each experiment conducted on a 96-well plate. Results for these controls are compared to historical results compiled in the historical database, as seen in **Section 16.0**.

6.1 Range Finder Testing

Antagonist range finding for coded substances consists of a seven-point 1:10 serial dilution using duplicate wells per concentration. Concentrations for comprehensive testing are selected based

on the response observed in range finder testing. If necessary, a second range finder test can be conducted to clarify the optimal concentration range to test (see **Section 14.0**).

6.2 Comprehensive Testing

Comprehensive antagonist testing for coded substances consists of 11-point serial dilutions, with each concentration tested in triplicate wells of the 96-well plate. Three separate experiments are conducted for comprehensive testing on three separate days, except during Phases III and IV of the validation effort, in which comprehensive testing experiments are conducted once (see **Section 15.0**).


7.0 MATERIALS FOR LUMI-CELL® ER ANTAGONIST TESTING

This section provides the materials needed to conduct LUMI-CELL® ER testing, with associated brand names/vendors² in brackets.

7.1 BG1Luc4E2 Cells:

Human ovarian cancer cell line stably transfected with a plasmid containing an estrogen response element (**Figure 7-1**) [XDS].

363 Figure 7-1 pGudLuc7.ERE Plasmid.



²Brand names and vendors should not be considered an endorsement by the U.S. Government or any member of the U.S. Government; such information is provided as examples.

365	7.2	Technical Equipment:
366	All techni	ical equipment may be obtained from Fisher Scientific International, Inc. (Liberty Lane
367	Hampton,	, NH, USA 03842). Equivalent technical equipment from another commercial source
368	can be use	ed.
369		• Analytical balance (Cat. No. 01-910-320)
370		• Berthold Orion 1 Microplate Luminometer [Berthold CatNo.: Orion 1 MPL3] or
371		equivalent and dedicated computer
372		• Biological safety hood, class II, and stand (Cat. No. 16-108-99)
373		• Centrifuge (low speed, tabletop with swinging bucket rotor) (Cat. No. 04-978-50
374		centrifuge, and 05-103B rotor)
375		• Combustion test kit (CO ₂ monitoring) (Cat. No. 10-884-1)
376		• Drummond diaphragm pipetter (Cat. No. 13-681-15)
377		• Freezers, -20°C (Cat. No. 13-986-150), and -70°C (Cat. No. 13-990-86)
378		• Hand tally counter (Cat. No. 07905-6)
379		• Hemocytometer, cell counter (Cat. No. 02-671-5)
380		• Light microscope, inverted (Cat. No. 12-561-INV)
381		• Light microscope, upright (Cat. No. 12-561-3M)
382		• Liquid nitrogen flask (Cat. No. 11-675-92)
383		• Micropipetter, repeating (Cat. No. 21-380-9)
384		• Pipetters, air displacement, single channel (0.5 –10µl (Cat. No. 21-377-191), 2 –
385		$20~\mu l$ (Cat. No. 21-377-287), $20-200~\mu l$ (Cat. No. 21-377-298), 200 - $1000~\mu l$
386		(Cat. No. 21-377-195))
387		• Refrigerator/freezer (Cat. No. 13-986-106A)
388		• Shaker for 96-well plates (Cat. No. 14-271-9)
389		• Sodium hydroxide (Cat. No. 5318-500)

390	• Sonicating water bath (Cat. No. 15-335-30)
391	• Tissue culture incubator with CO ₂ and temperature control (Cat. No. 11-689-4)
392	• Vacuum pump with liquid trap (side arm Erlenmeyer) (Cat. No. 01-092-29)
393	• Vortex mixer (Cat. No. 12-814)
394 395	Equipment should be maintained and calibrated as per GLP guidelines and individual laboratory SOPs.
396	7.3 Reference Standard, Controls, and Tissue Culture Supplies
397398399	All tissue culture reagents must be labeled to indicate source, identity, storage conditions and expiration dates. Tissue culture solutions must be labeled to indicate concentration, stability (where known), and preparation and expiration dates.
400 401	Equivalent tissue culture media and sera from another commercial source can be used, but must first be tested as described in Section 17.0 to determine suitability for use in this test method.
402 403	The following are the necessary tissue culture reagents and possible sources based on their use in the pre-validation studies:
404 405	• BackSeal-96/384, white adhesive bottom seal for 96-well and 384-well microplate [Perkin-Elmer, Cat. No. 6005199]
406	• 17 β-estradiol (CAS RN: 50-28-2) [Sigma-Aldrich, Cat. No. E8875]
407	• CellTiter-Glo® Luminescent Cell Viability Assay [Promega Cat. No. G7572]
408	• Cryovial, 2 mL (Corning Costar) [Fisher Scientific Cat. No. 03-374-21]
409	• Culture tube 13 x 100mm (case) [Thomas Scientific Cat. No.: 10009186R38] ³
410 411	 Culture tube, 50 mL conical (Corning Costar) [Fisher Scientific Cat. No. 05- 526C]
412	• DMSO, U.S.P. analytical grade. [Sigma-Aldrich, Cat. No. 34869-100ML]

³If glass tubes can not be obtained from Thomas Scientific, the preference is for flint glass, then lime glass, then borosilicate glass.

413 414 415	•	Dulbecco's Modification of Eagle's Medium (DMEM), containing 4.5 g/L glucose, with sodium pyruvate, without phenol red or L-glutamine [Mediatech/Cellgro, Cat. No. 17-205-CV]
416	•	Fetal Bovine Serum [Mediatech/Cellgro Cat. No. MT 35-010-CV]
417 418	•	Fetal Bovine Serum, charcoal/dextran treated, triple 0.1 µm sterile filtered [Hyclone, Cat. No. SH30068.03]
419	•	Flavone (CASRN: 525-82-6) [Sigma-Aldrich, Cat. No. F2003]
420	•	Gentamycin Sulfate (G418), 50 mg/mL [Mediatech/Cellgro Cat. No. 30-234-CR]
421	•	L-glutamine, 29.2 mg/mL [Cellgro, Cat. No. 25005-CI]
422	•	Luciferase Assay System (10-Pack) [Promega Cat. No. E1501]
423	•	Lysis Solution 5X [Promega, Cat. No. E1531]
424 425	•	Penicillin/streptomycin solution, 5000 I.U. penicillin, 5000 μ g/mL streptomycin [Cellgro, Cat. No. 30-001-CI].
426 427	•	Phosphate buffered saline (PBS, 1X) without calcium and magnesium [Cellgro, Cat. No. 21-040-CV]
428 429	•	Pipettes, serological: 2.0 mL [Sigma-Aldrich, Cat. No. P1736], 5.0 mL [Sigma-Aldrich, Cat. No. P1986], 25 mL [Sigma-Aldrich, Cat. No. P2486]
430	•	Raloxifene (CASRN 84449-90-1) [Sigma-Aldrich Cat. No. R1402]
431	•	RPMI 1640 medium, containing L-glutamine [Mediatech, Cat. No. 10-040-CV]
432 433 434	•	Tissue culture flasks (Corning-Costar): 25 cm ² (T25) [Fisher Cat. No. 10-126-28]; 75 cm ² (T75) [Fisher Cat. No. 10-126-37]; and 150 cm ² (T150) [Fisher Cat. No. 10-126-34]
435 436	•	Tissue culture plates (Corning-Costar): 96-well [Thomas Scientific Cat. No. 6916A05]
437 438	•	Trypsin (10X), 2.5% in Hank's balanced salt solution (HBSS), without calcium and magnesium, without phenol red [Cellgro, Cat. No. 25-054-CI].

463

component.

439	All reage	nt lot numbers and expiration dates must be recorded in the study notebook.
440	8.0	PREPARATION OF TISSUE CULTURE MEDIA AND SOLUTIONS
441 442		e culture media and media supplements must be quality tested before use in experiments ion 15.0).
443	8.1	RPMI 1640 Growth Medium (RPMI)
444 445	RPMI 16 (RPMI).	40 is supplemented with 0.9% Pen-Strep and 8.0% FBS to make RPMI growth medium
446	Procedure	e for one 549 mL bottle:
447 448		1. Remove FBS from -70°C freezer, and Pen-Strep from -20°C freezer and allow to equilibrate to room temperature.
449		2. Add 44 mL of FBS and 5 mL Pen-Strep to the bottle of RPMI 1640.
450		3. Label RPMI bottle as indicated in Section 7.3
451	Store at 2	2-8 °C for no longer than six months or until the shortest expiration date of any media
452	compone	nt.
453	8.2	Estrogen-Free DMEM Medium
454 455	DMEM i	s supplemented to contain 4.5% charcoal/dextran treated FBS, 1.9% L-glutamine, 0.9% b.
456	Procedure	e for one 539 mL bottle:
457 458		1. Remove charcoal/dextran treated FBS from -70°C freezer, and L-glutamine and Pen-Strep from -20°C freezer and allow to equilibrate to room temperature.
459 460		2. Add 24 mL of charcoal/dextran treated FBS, 10 mL L-glutamine, and 5 mL Pen- Strep to one 500 mL bottle of DMEM.
461		3. Label estrogen-free DMEM bottle as indicated in Section 7.3
462	Store at 2	2-8°C for no longer than six months or until the shortest expiration date of any media

464	8.3	1X Trypsin Solution
465 466		sin solution is prepared by dilution from a 10X premixed stock solution. The 10X stock should be stored in 10 mL aliquots in a -20°C freezer.
467	Procedu	re for making 100 mL of 1X trypsin:
468 469		 Remove a 10mL aliquot of 10X trypsin from -20°C freezer and allow to equilibrate to room temperature.
470 471		2. Aliquot 1 mL Trypsin (10X) along with 9 mL of 1X PBS into ten 15 mL centrifuge tubes.
472		3. Label 1X trypsin aliquots as indicated in Section 7.3
473	1X Tryps	sin should be stored at -20°C.
474	8.4	1X Lysis Solution
475 476		lution is prepared by dilution from a 5X premixed stock solution. Both the 5X and 1X s can be repeatedly freeze-thawed.
477	The proc	cedure for making 10 mL of 1X lysis solution:
478		1. Thaw the 5X Promega Lysis solution and allow it to reach room temperature.
479		2. Remove 2 mL of 5X solution and place it in a 15 mL conical centrifuge tube.
480		3. Add 8 mL of distilled, de-ionized water to the conical tube.
481		4. Cap and shake gently until solutions are mixed.
482	Store at	-20°C for no longer than 1 year from receipt.
483	8.5	Reconstituted Luciferase Reagent
484	Lucifera	se reagent consists of two components, luciferase buffer and lyophilized luciferase
485	substrate	5 .
486	For long	-term storage, unopened containers of the luciferase buffer and lyophilized luciferase

substrate can be stored at -70°C for up to six months.

To reconstitute luciferase reagent:

487

489		1.	Remove luciferase buffer and luciferase substrate from -70°C freezer and allow		
490			them to equilibrate to room temperature.		
491		2.	Add 10 mL of luciferase buffer solution to luciferase substrate container and swirl		
492			or vortex to mix, the Luciferase substrate should readily go into solution.		
493		3.	Luciferase substrate should readily go into solution.		
494		4.	After solutions are mixed aliquot to a 15mL centrifuge tube.		
495		5.	Store complete solution at –20°C.		
496	Reconst	tituted	luciferase reagent is stable for 1 month at -20°C.		
497	9.0	OV	ERVIEW OF PROPAGATION AND EXPERIMENTAL PLATING OF		
498		BG	G1Luc4E2 CELLS		
499	The BG	1Luc	4E2 (BG-1) cells are stored in liquid nitrogen in 2 mL cryovials. BG-1 cells are		
500	grown a	grown as a monolayer in tissue culture flasks in a dedicated tissue culture incubator at $37^{\circ}\text{C} \pm$			
501	1°C, 90% \pm 5% humidity, and 5.0% \pm 1% CO ₂ /air. The cells should be examined on a daily basis				
502	during working days under an inverted phase contrast microscope, and any changes in				
503	morpho	logy a	and adhesive properties must be noted in the study notebook.		
504	Two T1	50 fla	sks containing cells at 80% to 90% confluence will usually yield a sufficient		
505	number	of cel	lls to fill three 96-well plates for use in experiments.		
506	9.1	Pro	ocedures for Thawing Cells and Establishing Tissue Cultures		
507	Warm a	ll tiss	ue culture media and solutions to room temperature by placing them under the		
508	tissue c	ulture	hood several hours before use.		
509	All tissu	ie cult	ture media, media supplements, and tissue culture plasticware must be quality		
510	tested b	efore	use in experiments (Section 17.0).		
511	9.1.1	Tha	awing Cells		
512		1.	Remove a cryovial of frozen BG-1 cells from the liquid nitrogen flask.		
513		2.	Facilitate rapid thawing by loosening the top slightly (do not remove top) to		
514			release trapped gasses and retightening it. Roll vial between palms.		

515		3.	Use a micropipette to transfer cells to a 50 mL conical centrifuge tube.
516		4.	Rinse cryovial twice with 1X PBS and add PBS rinse material to the conical tube.
517		5.	Add 20 mL of RPMI to the conical tube.
518 519		6.	Centrifuge at 1000 x g for eight min. If a pellet of cells has not formed, centrifuge for an additional 5 minutes.
520 521		7.	Aspirate media from pellet and re-suspend it in 5 mL RPMI, drawing the pellet repeatedly through a 1.0 mL serological pipette to break up any clumps of cells.
522 523		8.	Transfer cells to a T25 flask, place them in an incubator (see conditions in Section 9.0) and grow to 80% to 90% confluence (approximately 48 to 72 hrs).
524	9.1.2	Est	ablishing Tissue Cultures
525	Once cel	ls ha	ve reached 80% to 90% confluence, transfer the cells to a T75 flask by performing,
526	for exam	ple, t	the following steps:
527		1.	Remove the T25 flask from the incubator.
528 529		2.	Aspirate the RPMI, then add 5 mL 1X PBS, making sure that the cells are coated with PBS.
530 531		3.	Aspirate 1X PBS, then add 1 to 2 mL 1X trypsin to the T25 flask, gently swirling the flask to coat all cells with the trypsin.
532		4.	Place the flask in an incubator (see conditions in Section 9.0) for 5 to 10 min.
533 534		5.	Detach cells by hitting the side of the flask sharply against the palm or heel of the hand.
535 536 537		6.	Confirm cell detachment by examination under an inverted microscope. If cells have not detached, return the flask to the incubator for an additional 2 minutes, then hit the flask again.
538 539		7.	After cells have detached, add 5 mL PBS, and transfer the suspended cells to a 50 mL centrifuge tube. Wash the flask one additional time with 5 mL PBS.
540 541		8.	Immediately add 20 mL RPMI to the conical tube to inhibit further cellular digestion by residual trypsin

542543	9.	Pellet the cells by centrifugation, as described in Section 9.1.1 , and re-suspend the cells in 10 mL RPMI medium.
544545	10.	Draw the pellet repeatedly through a 25 mL serological pipette to break up clumps of cells
546 547	11.	Transfer cells to a T75 flask, then place the flask in an incubator (see conditions in Section 9.0) and grow to 80% to 90% confluence (approximately 48 to 72 hrs).
548549		ve reached 80% to 90% confluency, transfer them into a T150 flask by performing, he following steps:
550 551	12.	Remove the T75 flask from the incubator, aspirate the old media and add 5 mL 1X PBS.
552553	13.	Aspirate 1X PBS, add 2 mL of 1X trypsin to the flask, and place it in an incubator (see conditions in Section 9.0) for 5 to 10 min.
554555	14.	Repeat steps 5 through 11 in Section 9.1.2 , re-suspending the pellet in 20 mL of RPMI.
556 557	15.	Transfer cells to a T150 flask and place it in the incubator (see conditions in Section 9.0) and grow to 80% to 90% confluence (approximately 48 to 72 hrs).
558	16.	Remove the T150 flask from the incubator.
559	17.	Aspirate the RPMI and add 5 mL 1X PBS.
560561	18.	Aspirate $1X$ PBS and add 3 mL $1X$ trypsin to the T150 flask, making sure that the cells are coated with the trypsin.
562	19.	Incubate cells in an incubator (see conditions in Section 9.0) for 5 to 10 min.
563564	20.	Detach cells by hitting the side of the flask sharply against the palm or heel of the hand.
565566567	21.	Confirm cell detachment by examination under an inverted microscope. If cells have not detached, return the flask to the incubator for an additional 2 minutes, then hit the flask again.


568569570	22.	After cells have detached, add 5mL 1X PBS and transfer the suspended cells from the T150 flask to a 50 mL conical tube. Add an additional 5 mL PBS to the flask, then transfer to the 50 mL conical tube.
571 572	23.	Immediately add 20 mL RPMI to the conical tube to inhibit further cellular digestion by residual trypsin.
573 574	24.	Centrifuge at 1000 x g for eight minutes. If a pellet of cells has not formed, centrifuge for an additional 5 minutes.
575576577	25.	Aspirate the media from the pellet and re-suspend it in 40 mL RPMI, drawing the pellet repeatedly through a 25 mL serological pipette to break up any clumps of cells.
578579580	26.	Transfer 20 mL of cell suspension to each of two T150 flasks, place them in an incubator (see conditions in Section 9.0) and grow to 80% to 90% confluence (approximately 48 to 72 hrs).
581 582		going Tissue Culture Maintenance, Conditioning in Estrogen-free Medium,
583 584 585	environment	g procedure is used to condition the BG1Luc4E2 cells to an estrogen-free prior to plating the cells in 96-well plates for analysis of estrogen dependent uciferase activity.
586 587 588 589 590	flasks into for will use the R	ssue culture maintenance and estrogen-free conditioning, split the two T150 culture are T150 flasks. Two of these flasks will be used for continuing tissue culture and a PMI media mentioned above. The other two flasks will be cultured in estrogen-free experimental use. Extra care must be taken to avoid contaminating the estrogen-free MI.
592 593	1. 2.	Remove both T150 flasks from the incubator. Aspirate the medium and rinse the cells with 5 mL 1X PBS.
594 595	3.	Aspirate 1X PBS, then add 3 mL 1X trypsin to the flasks, gently swirling the flask to coat all cells with the trypsin.

596		4.	Incubate cells in the incubator (see conditions in Section 9.0) for 5 to 10 min.
597 598		5.	Detach cells by hitting the side of the flask sharply against the palm or heel of the hand.
599 600 601		6.	Confirm cell detachment by examination under an inverted microscope. If cells have not detached, return the flask to the incubator for an additional 2 minutes, then hit the flask again.
602 603		7.	After cells have detached, add 5 mL 1X PBS to the first T150 flask and transfer the suspended cells to the second T150 flask.
604 605		8.	Transfer the contents of both flasks to a 50 mL conical tube. Repeat step 7 with an additional 5 mL 1X PBS and transfer to the 50 mL conical tube.
606 607		9.	Immediately add 20 mL estrogen-free DMEM to the 50 mL conical tube to inhibit further cellular digestion by residual trypsin.
608 609		10.	Centrifuge at 1000 x g for eight minutes. If a pellet of cells has not formed, centrifuge for an additional 5 minutes.
610611612		11.	Aspirate media from pellet and re-suspend it in 4 mL estrogen-free DMEM, drawing the pellet repeatedly through a 1 mL serological pipette to break up clumps of cells.
613 614	At this po		cells are ready to be divided into the ongoing tissue culture and estrogen-free groups.
615 616	9.2.1	<u>Ong</u> 1.	Add 20 mL RPMI to two T150 flasks.
617		2.	Add 220 μL G418 to the RPMI in the T150 flasks
618		3.	Add 1 mL of cell suspension from Section 9.2 step 11 to each flask.
619 620		4.	Place T150 flasks in tissue culture incubator (see conditions in Section 9.0) and grow to 80% to 90% confluence (approximately 48 to 72 hrs).
621 622		5.	Tissue culture medium may need to be changed 24 hours after addition of G418 to remove cells that have died because they do not express reporter plasmid.

623		6.	G418 does not need to be added to the flasks a second time.
624		7.	Repeat Section 9.2 steps 1-11 for ongoing tissue culture maintenance.
625	9.2.2	<u>Co</u>	anditioning in Estrogen-free Medium
626		1.	Add 20 mL estrogen-free DMEM to two T150 flasks.
627		2.	Add 150 µL G418 to the estrogen-free DMEM in the T150 flasks.
628		3.	Add 1 mL of cell suspension from Section 9.2 step 11 to each flask.
629		4.	Tissue culture medium may need to be changed 24 hours after addition of G418 to
630			remove cells that have died because they do not express reporter plasmid.
631		5.	G418 does not need to be added to the flasks a second time.
632		6.	Place the T150 flasks in the incubator (see conditions in Section 9.0) and grow to
633			80% to 90% confluence (approximately 48 to 72 hrs).
634	9.2.3	<u>Pla</u>	ating Cells Grown in Estrogen-free DMEM for Experimentation
635		1.	Remove the T150 flasks that have been conditioned in estrogen-free DMEM for
636			48 to 72 hours from the incubator.
637		2.	Aspirate the medium, then rinse the cells with 5 mL 1X PBS.
638		3.	Aspirate 1X PBS, then add 3 mL 1X trypsin to the flasks, gently swirling the flask
639			to coat all cells with the trypsin.
640		4.	Place the flasks in an incubator (see conditions in Section 9.0) for 5 to 10 min.
641		5.	Detach cells by hitting the side of the flask sharply against the palm or the heel of
642			the hand.
643		6.	Confirm cell detachment by examination under an inverted microscope. If cells
644			have not detached, return the flask to the incubator for 2 additional minutes, then
645			hit the flask again.
646		7.	After cells have detached, add 5 mL 1X PBS and transfer the suspended cells
647			from the T150 flask to a 50 mL conical tube. Add an additional 5 mL PBS to the
648			flask, then transfer to the 50 mL conical tube.

- 8. Immediately add 20 mL estrogen-free DMEM to each conical tube to inhibit further cellular digestion by residual trypsin.
- 9. Centrifuge at 1000 x g for eight minutes. If a pellet of cells has not formed, centrifuge for an additional 5 minutes.
- 10. Aspirate off the media from the pellet and re-suspend it in 20 mL DMEM, drawing the pellet repeatedly through a 25 mL serological pipette to break up any clumps of cells.
- 11. Pipette 15 µL of the cell suspension into the "v" shaped slot on the hemocytometer. Ensure that the solution covers the entire surface area of the hemocytometer grid, and allow cells to settle before counting.
- 12. Using 100x magnification, view the counting grid.
- 13. The counting grid on the hemocytometer consists of nine sections, four of which are counted (upper left, upper right, lower left, and lower right, see **Figure 9-1**). Each section counted consists of four by four grids. Starting at the top left and moving clockwise, count all cells in each of the four by four grids. Some cells will be touching the outside borders of the square, but only count those that touch the top and right borders of the square. This value is then used in the calculation below to get to the desired concentration of 200,000 cells/mL.

Figure 9-1 Hemocytometer Counting Grid.



The volume of each square is 10⁻⁴ mL, therefore: 668 Cells/mL = (average number per grid) x 10^{-4} mL. x 1/(starting dilution). 669 670 Starting dilution: 20mL (for T150 flasks) 671 672 Harvested cells for a T150 flask are suspended in 20 mL of estrogen-free DMEM and sampled 673 for determination of concentration of cells/mL. 674 675 Example Calculation: 676 Grids 1, 2, 3, and 4 are counted and provide the following data: 677 o 50, 51, 49, and 50: average number of cells per grid is equal to 50. Cells/mL = 50 cells per grid \div 10⁻⁴ mL volume of grid = 50 X 10⁻⁴ cells/mL (or 500,000 678 679 cells/mL) 680 Total # of Cells Harvested = 500,000 cells/mL x 20 mL 681 Desired Concentration (or Concentration Final) = 200,000 cells/mL 682 Formula: (Concentration Final x Volume Final = Concentration Initial x Volume Initial) 683 Concentration Final = 200,000 cells/mL 684 Concentration Initial = 500,000 cells/mL 685 Volume $I_{nitial} = 20 \text{ mL}$ 686 Volume Final – to be solved for. 687 Therefore: 200,000 cells/mL x Volume Final = 500,000 cells/mL x 20 mL 688 Solving for Volume $_{Final}$ we find = 50 mL 689 Therefore, add 30 mL of estrogen-free DMEM to the cell suspension for a total volume of 50 690 mL, which will yield the desired concentration of 200,000 cells/mL for plating. 691 14. This dilution scheme will give a concentration of 200,000 cells/mL. 200 μL of 692 this cell suspension is used for each well of a 96-well plate (i.e., 40,000 cells per 693 well).

694		15.	Remove a 96-well plate from its sterile packaging. Use a repeater pipetter to
695			pipette 200 μL of cell suspension into each well to be used for the testing of
696			coded substances, reference standard and controls (note: add 200 μL of estrogen-
697			free DMEM only to any wells not being used for testing).
698		16.	Incubate plate(s) in an incubator (see conditions in Section 9.0) for a minimum of
699			24 hours, but no longer than 48 hours before dosing.
700	Two T1	50 fla	sks containing cells at 80% to 90% confluence will typically yield sufficient cells
701	to fill fo	ur 96	-well plates (not including the perimeter wells).
702	10.0	PR	EPARATION OF TEST SUBSTANCES
703	The solv	vent u	sed for dissolution of test substances is 100% DMSO. All test substances should be
704	allowed	to eq	uilibrate to room temperature before being dissolved and diluted. Test substance
705	solution	s (exc	cept for reference standards and controls) should not be prepared in bulk for use in
706	subsequ	ent te	sts. Test substances are to be used within 24 hours of preparation. Solutions should
707	not have	e notic	ceable precipitate or cloudiness.
708	All info	rmati	on on weighing, solubility testing, and calculation of final concentrations for test
709	substanc	ces, re	eference standards and controls is to be recorded in the study notebook.
710	10.1	De	termination of Test Substance Solubility
711		1.	Prepare a 200 mg/mL solution of the test substance in 100% DMSO in a 4 mL
712			conical tube.
713		2.	Vortex to mix.
714		3.	If the test substance does not dissolve at 200 mg/mL, prepare a 20 mg/mL
715			solution and vortex as above.
716		4.	If the test substance does not dissolve at 20 mg/mL solution, prepare a 2 mg/mL
717			solution in a 4 mL conical tube and vortex as above.
718		5.	If the test substance does not dissolve at 2 mg/mL, prepare a 0.2 mg/mL solution
719			in a 4 mL conical tube and vortex as above.

- 720 6. Continue testing, using 1/10 less substance in each subsequent attempt until test substance is solubilized in DMSO.
- Once the test substance has fully dissolved in 100% DMSO, the test substance is ready to be
- 723 used for LUMI-CELL® ER testing.
- The Testing Facility shall forward the results from the solubility tests assay to the SMT through
- the designated contacts in electronic format and hard copy upon completion of testing.

726 11.0 PREPARATION OF REFERENCE STANDARD, CONTROL AND TEST

- 727 SUBSTANCE STOCK SOLUTIONS FOR RANGE FINDER AND
- 728 COMPREHENSIVE TESTING
- All information on preparation of test substances, reference standards and controls is to be
- 730 recorded in the study notebook.
- 731 11.1 Preparation of Ral/E2 Stock Solutions
- E2 and raloxifene stocks are prepared separately and then combined into Ral/E2 stocks, which
- are then used to prepare dosing solutions in **Section 12**.
- 734 11.1.1 E2 Stock Solution
- The final concentration of the E2 stock solution is $5.0 \times 10^{-3} \,\mu\text{g/mL}$. Prepare the E2 stock as
- 736 shown in **Table 11-1**.

737 Table 11-1 Preparation of E2 Stock Solution

Step #	Action	DMSO	E2 Concentration
1	Make a 10 mg/mL stock solution in 100% DMSO in a 4mL vial.	-	10 mg/mL
2	Transfer 10 μL E2 solution from Step #1 to a new 4 mL vial.	Add 990 μL of 100% DMSO. Vortex to mix.	100 μg/mL
3	Transfer 10 μL E2 solution from Step #2 to a new 4mL vial.	Add 990 μL of 100% DMSO. Vortex to mix.	1 μg/mL
4	Transfer 100 μL E2 solution from Step #3 to a new glass container large enough to hold 15 mL.	Add 9.90 mL of 100% DMSO. Vortex to mix.	1.0 x 10 ⁻² μg/mL
5	Transfer 5 mL E2 solution from Step #4 to a new glass container large enough to hold 15 mL	Add 5 mL of 100% DMSO. Vortex to mix.	5.0 x 10 ⁻³ μg/mL

738 11.1.2 Raloxifene Stock Solution

739 Prepare a 2.5 µg/mL raloxifene working stock solution as shown in **Table 11-2**.

740 Table 11-2 Preparation of Raloxifene Stock Solution

Step #	Action	DMSO	Raloxifene Concentration
1	Make a 10 mg/mL solution of raloxifene in a 4 mL glass vial.	-	1.0 x 10 ⁴ μg/mL
2	Transfer 10 μL raloxifene solution from Step #1 to a new 4 mL vial.	Add 990 μL of 100% DMSO. Vortex to mix.	100 μg/mL
3	Transfer 150 μL raloxifene solution from Step #2 to a new 4 mL vial.	Add 2.850 mL of 100% DMSO. Vortex to mix.	5 μg/mL
4	Transfer 1.5 mL raloxifene solution from Step #3 to a new 13 mm test tube.	Add 1.5 mL of 100% DMSO. Vortex to mix.	2.5 μg/mL

741

742 11.2 Ral/E2 Range Finder Testing Stock

743 11.2.1 Raloxifene Dilutions

Number three 4 mL vials with the numbers 1 to 3 and use the raloxifene solution prepared in

745 **Section 11.1.2** to make raloxifene dilutions as shown **Table 11-3**.

746 Table 11-3 Preparation of Raloxifene Dilutions for Range Finder Testing

Step #	Action	DMSO	Raloxifene Concentration
1	Transfer 250 μ L of the 2.5 μ g/mL raloxifene working stock solution to a 4 mL tube	Add 750 μL of 100% DMSO and vortex	6.25 x 10 ⁻¹ μg/mL
2	Transfer 500 μL of the 6.25 x 10 ⁻¹ μg/mL raloxifene solution to a 4 mL tube	Add 500 μL of 100% DMSO and vortex	3.13 x 10 ⁻¹ μg/mL
3	Transfer 250 μL of the 3.13 x 10 ⁻¹ μg/mL raloxifene solution to a 4 mL tube	Add 750 μL of 100% DMSO and vortex	7.81 x 10 ⁻² μg/mL
4	Transfer 125 μL of the 7.81 x 10 ⁻² μg/mL raloxifene solution to a 4 mL tube	Add 375 μL of 100% DMSO and vortex	1.95 x 10 ⁻² μg/mL

747

748 11.2.2 <u>Preparation of Ral/E2 Range Finder Working Stocks:</u>

Label three 4 mL conical tubes with numbers 1 through 3 and add 500 μ L of the 5 x 10^{-3} μ g/mL

750 E2 solution prepared in **Section 11.1.1** to each tube. Add 500 μ L of the 3.13 x 10⁻¹, 7.81 x 10⁻²,

- and 1.95 x 10^{-2} µg/mL raloxifene solutions prepared in **Section 11.2.1** to tubes 1, 2, and 3
- 752 respectively. Vortex each tube to mix. The final concentrations for raloxifene and E2 are listed in
- 753 **Table 11-4**.

Table 11-4 Concentrations of Raloxifene and E2 in the Ral/E2 Range Finder Working Stocks

Tube #	Raloxifene (µg/ml)	E2 (μg/ml)
1	1.56 x 10 ⁻¹	2.5 x 10 ⁻³
2	3.91 x 10 ⁻²	2.5 x 10 ⁻³
3	9.77 x 10 ⁻³	2.5 x 10 ⁻³

754

755

757 11.3 Ral/E2 Comprehensive Testing Stock

758 11.3.1 Raloxifene Dilutions

- 759 Use the raloxifene solution prepared in **Section 11.1.2** to make a nine-point serial dilution of
- 760 raloxifene as shown **Table 11-5**.

761 Table 11-5 Preparation of Raloxifene Dilutions for Comprehensive Testing

Step #	Action	DMSO	Discard	Raloxifene Concentration
1	Transfer 500 µL of the raloxifene working stock solution to a new 4 mL vial.	-	-	2.5 μg/mL
2	Transfer 500 µL of the raloxifene working stock solution to a new 4 mL vial.	Add 500 µL of 100% DMSO. Vortex to mix.	-	1.25 μg/mL
3	Transfer 500 µL raloxifene solution from Step #2 to a new 4 mL vial.	Add 500 µL of 100% DMSO. Vortex to mix.	-	6.25 x 10 ⁻¹ μg/mL
4	Transfer 500 µL raloxifene solution from Step #3 to a new 4 mL vial.	Add 500 µL of 100% DMSO. Vortex to mix.	-	3.13 x 10 ⁻¹ μg/mL
5	Transfer 500 µL raloxifene solution from Step #4 to a new 4 mL vial.	Add 500 µL of 100% DMSO. Vortex to mix.	-	1.56 x 10 ⁻¹ μg/mL
6	Transfer 500 µL raloxifene solution from Step #5 to a new 4 mL vial.	Add 500 µL of 100% DMSO. Vortex to mix.	-	7.81 x 10 ⁻² µg/mL

Step #	Action	DMSO	Discard	Raloxifene Concentration
7	Transfer 500 μL raloxifene solution from Step #6 to a new 4 mL vial.	Add 500 μL of 100% DMSO. Vortex to mix.	-	3.91 x 10 ⁻² μg/mL
8	Transfer 500 μL raloxifene solution from Step #7 to a new 4 mL vial.	Add 500 μL of 100% DMSO. Vortex to mix.		1.95 x 10 ⁻² μg/mL
9	Transfer 500 μL raloxifene solution from Step #8 to a new 4 mL vial.	Add 500 μL of 100% DMSO. Vortex to mix.	Discard 500 µL from Tube #9	9.77 x 10 ⁻³ μg/mL

763

765

11.3.2 Preparation of Ral/E2 Comprehensive Testing Working Stocks:

Add 500 μ L of the 5 x 10⁻³ μ g/mL E2 solution prepared in **Section 11.1.1** to each of the 9

raloxifene dilution vials (including the working stock solution in Tube #1). Vortex each tube to

mix. The final concentrations for raloxifene and E2 are listed in **Table 11-6**.

767 Table 11-6 Concentrations of Raloxifene and E2 in the Ral/E2 Working Stocks

Tube #	Raloxifene (µg/mL)	E2 (μg/mL)
1	1.25	2.5×10^{-3}
2	6.25 x 10 ⁻¹	2.5×10^{-3}
3	3.13×10^{1}	2.5×10^{-3}
4	1.56 x 10 ⁻¹	2.5×10^{-3}
5	7.81×10^2	2.5×10^{-3}
6	3.91×10^{-2}	2.5×10^{-3}
7	1.95 x 10 ⁻²	2.5×10^{-3}
8	9.77 x 10 ⁻³	2.5×10^{-3}
9	4.88×10^{-3}	2.5×10^{-3}

768

769

771

772

773

774

11.4 Flavone/E2 Stock Solution

To prepare the flavone/E2 stock solution, proceed as follows:

1. Prepare 1 mL of 5 mg/mL flavone

2. Add 1 mL of the 5x10⁻³ μg/mL E2 (prepared as in **Section 11.1.1**) to the 10 mg/mL flavone. This will make a working solution of 2.5 mg/mL flavone with 2.5x10⁻³ μg/mL E2.

775 776 777	12.0	PREPARATION OF REFERENCE STANDARD, CONTROL AND TEST SUBSTANCE DOSING SOLUTIONS FOR RANGE FINDER AND COMPREHENSIVE TESTING
778 779	12.1	Preparation of Reference Standard and Control Dosing Solutions for Range Finder Testing
780 781 782 783 784	duplicate included of	ader testing is conducted on 96-well plates using three concentrations of Ral/E2 in as the reference standard. Three replicate wells for the DMSO, and E2 controls are on each plate. In a solutions of test substance concentrations are to be expressed as µg/mL in the study and in all laboratory reports.
785		olutions are to be used within 24 hours of preparation.
786 787 788 789 790 791 792	12.1.1	 Preparation of Ral/E2 Reference Standard Range Finder Dosing Solutions Label three 13 mm glass tubes with the numbers 1 to 3. Add 6 μL of Ral/E2 stock from tube #1 from Section 11.2.2 to the 13 mm glass test tube labeled #1. Add 6 μL of Ral/E2 stock from tube #2 from Section 11.2.2 to the 13 mm glass test tube labeled #2. Repeat for tube #3. Add 600 μL of estrogen-free DMEM to each tube and vortex.
793794795	12.1.2	 Preparation of DMSO Control Range Finder Dosing Solution Add 8 μL of 100% DMSO to a 13 mm glass test tube. Add 800 μL of estrogen-free DMEM to each tube and vortex.
796 797 798 799	12.1.3	 Preparation of E2 Control Range Finder Dosing Solution Add 4 μL of the E2 stock from Section 11.1.1 to a 13 mm glass test tube. Add 4 μL of 100% DMSO to the tube. Add 800 μL of estrogen-free DMEM to the tube and vortex to mix.

801

802

803

804

805

806

807

808

809

810

811

812

813

12.2 Preparation of Test Substance Dosing Solutions for Range Finder Testing

Range finder experiments are used to determine the concentrations of test substance to be used during comprehensive testing. Antagonist range finding for coded substances consists of seven-point 1:10 serial dilutions in duplicate.

To prepare test substance dosing solutions:

1. Label two sets of seven glass 13 mm test tubes with the numbers 1 through 7 and place them in a test tube rack. Perform a serial dilution of test substance as shown in **Table 12-1** using one set of tubes.

Table 12-1 Preparation of Test Substance Serial Dilution for Range Finder Testing

Tube #	100% DMSO	Test Substance ¹	Final Volume
1	-	100 μL of test substance solution from Section 10.1	100 μL
2	90 μL	10 μL of test substance solution from Section 10.1	100 μL
3	90 μL	10 μL from Tube #2	100 μL
4	90 μL	10 μL from Tube #3	100 μL
5	90 μL	10 μL from Tube #4	100 μL
6	90 μL	10 μL from Tube #5	100 μL
7	90 μL	10 μL from Tube #6	100 μL

¹Vortex tubes #2 through 6 before removing test substance/DMSO solution to place in the next tube in the series.

2. Transfer test substance/DMSO solutions to the second set of labeled tubes and add E2 as shown in **Table 12-2**.

Table 12-2 Addition of E2 to Test Substance Serial Dilution for Range Finder Testing

Tube Number	Test Substance	E2	Estrogen- free DMEM ³	Final Volume
1	Transfer 4 µL of test substance from Tube #1 in Section 12.2 step 1 to a new tube	Add 4 μL of the 5 x 10 ⁻³ μg/mL E2 solution prepared in Section 11.1.1 . Vortex to mix.	800 μL	808 μL
2	Transfer 4 µL of test substance from Tube #2 to a new tube	Add 4 μL of the 5 x 10 ⁻³ μg/mL E2 solution prepared in Section 11.1.1 Vortex to mix.	800 μL	808 μL

Tube Number	Test Substance	E2	Estrogen- free DMEM ³	Final Volume
3	Transfer 4 µL of test substance from Tube #3 to a new tube	Add 4 µL of the 5 x 10 ⁻³ µg/mL E2 solution prepared in Section 11.1.1 . Vortex to mix.	800 μL	808 μL
4	Transfer 4 µL of test substance from Tube #4 to a new tube	Add 4 µL of the 5 x 10 ⁻³ µg/mL E2 solution prepared in Section 11.1.1 . Vortex to mix.	800 μL	808 μL
5	Transfer 4 µL of test substance from Tube #5 to a new tube	Add 4 µL of the 5 x 10 ⁻³ µg/mL E2 solution prepared in Section 11.1.1 . Vortex to mix.	800 μL	808 μL
6	Transfer 4 µL of test substance from Tube #6 to a new tube	Add 4 µL of the 5 x 10 ⁻³ µg/mL E2 solution prepared in Section 11.1.1 . Vortex to mix.	800 μL	808 μL
7	Transfer 4 µL of test substance from Tube #7 to a new tube	Add 4 μL of the 5 x 10 ⁻³ μg/mL E2 solution prepared in Section 11.1.1 . Vortex to mix.	800 μL	808 μL

Determination of whether a substance is positive in range finder testing and selection of starting concentrations for comprehensive testing will be discussed in **Section 14.0**.

12.3 Preparation of Reference Standard and Control Dosing Solutions for Comprehensive Testing

Comprehensive testing is conducted on 96-well plates using nine concentrations of Ral/E2 in duplicate as the reference standard. Four replicate wells for the DMSO, E2 and flavone/E2 controls are included on each plate.

All "dosing solutions" of test substance concentrations are to be expressed as $\mu g/mL$ in the study notebook and in all laboratory reports.

Store dosing solutions at room temperature. Use within 24 hours of preparation.

12.3.1 <u>Preparation of Ral/E2 Reference Standard Dosing Solutions for Comprehensive</u> Testing

In preparation for making Ral/E2 1:2 serial dilutions, label two sets of nine glass 13 mm test tubes with the numbers 1 through 9 and place them in a test tube rack. Tube number 1 will contain the highest concentration of raloxifene (**Table 12-3**).

Table 12-3 Preparation of Ral/E2 Reference Standard Dosing Solution for Comprehensive Testing

Tube Number	Ral/E2 Stock	Estrogen- free DMEM	Final Volume
1	6 μL of Tube #1 from Section 11.3.2	600 μL	606 μL
2	6 μL of Tube #2 from Section 11.3.2	600 μL	606 μL
3	6 μL of Tube #3 from Section 11.3.2	600 μL	606 μL
4	6 μL of Tube #4 from Section 11.3.2	600 μL	606 μL
5	6 μL of Tube #5 from Section 11.3.2	600 μL	606 μL
6	6 μL of Tube #6 from Section 11.3.2	600 μL	606 μL
7	6 μL of Tube #7 from Section 11.3.2	600 μL	606 μL
8	6 μL of Tube #8 from Section 11.3.2	600 μL	606 μL
9	6 μL of Tube #9 from Section 11.3.2	600 μL	606 μL

832

833

834

835

837

839

841

825

826

827

828

829

830

831

12.3.2 Preparation of DMSO Control Comprehensive Testing Dosing Solution

- 1. Add 10 μL of 100% DMSO to a 13 mm glass test tube.
- 2. Add 1000 µL of estrogen-free DMEM to the tube and vortex to mix.

836 12.3.3 Preparation of E2 Control Comprehensive Testing Dosing Solution

- 1. Add 5 μL of the E2 stock from **Section 11.1.1** to a 13 mm glass test tube.
- 838 2. Add 5 μ L of 100% DMSO to the tube.
 - 3. Add 1000 µL of estrogen-free DMEM to the tube and vortex to mix.

840 12.3.4 <u>Preparation of Flavone/E2 Control Comprehensive Dosing Solution</u>

- 1. Add 10 μL of flavone/E2 from **Section 11.4** to a 13 mm glass test tube.
- 2. Add 1000 μL of estrogen-free DMEM to the tube and vortex to mix.

843	12.4 Preparation of Test Substance Dosing Solutions for Comprehensive Testing
844	Comprehensive testing experiments are used to determine whether a substance possesses ER
845	antagonist activity in the LUMI-CELL® ER test method. Antagonist comprehensive testing for
846	coded substances consists of either an 11-point 1:2 serial dilution, or an 11-point 1:5 serial
847	dilution with each concentration tested in triplicate wells of the 96-well plate.
848	12.4.1 Preparation of Test Substance 1:2 Serial Dilutions for
849	Comprehensive Testing
850	Start the 11-point serial dilution according to criteria in Section 14.0 .
851	To make test substance 1:2 serial dilutions for comprehensive testing:
852	1. label eleven 4 mL conical tubes with numbers 1 through 11 and place them in a
853	tube rack
854	2. label eleven 13 mm glass test tubes with numbers 1 through 11, place them in a
855	tube rack and add 800 μL of estrogen-free DMEM to each tube
856	Prepare dilution of test substance as shown in Table 12-4 .
857	

858 859

860

861

862

863

864

865

866

867

868

869

870

Table 12-4 Preparation of Test Substance 1:2 Serial Dilutions for Comprehensive Testing

Tube Number	100% DMSO	Test Substance ¹	Discard	E2 Testing Stock	Estrogen- free DMEM ²	Final Volume
1	-	4 μL of test substance solution from Section 10.2.4 step 1	-	4 μL	800 μL	808 μL
2	4 μL	4 μL of test substance solution from Section 10.2.4 step 1	-	4 μL	800 μL	808 μL
3	4 μL	4 μL from Tube #2	-	4 μL	800 μL	808 μL
4	4 μL	4 μL from Tube #3	-	4 μL	800 μL	808 μL
5	4 μL	4 μL from Tube #4	-	4 μL	800 μL	808 μL
6	4 μL	4 μL from Tube #5	-	4 μL	800 μL	808 μL
7	4 μL	4 μL from Tube #6	-	4 μL	800 μL	808 μL
8	4 μL	4 μL from Tube #7	-	4 μL	800 μL	808 μL
9	4 μL	4 μL from Tube #8	-	4 μL	800 μL	808 μL
10	4 μL	4 μL from Tube #9	-	4 μL	800 μL	808 μL
11	4 μL	4 μL from Tube #10	4 μL	4 μL	800 μL	808 μL

¹Vortex tubes #2 through 10 before removing test substance/DMSO solution to place in the next tube in the series. ²Vortex all tubes to mix media, test substance, and E2.

12.4.2 Preparation of Test Substance 1:5 Serial Dilutions for

Comprehensive Testing

Start the 11-point serial dilution according to criteria in **Section 14.0**.

To make test substance 1:5 serial dilutions for comprehensive testing:

- label eleven 4 mL conical tubes with numbers 1 through 11 and place them in a tube rack
- 2. label eleven 13 mm glass test tubes with numbers 1 through 11, place them in a tube rack and add 800 µL of estrogen-free DMEM to each tube

Prepare dilution of test substance as shown in Table 12-5.

Table 12-5 Preparation of Test Substance 1:5 Dilutions for Comprehensive Testing

Tube Number	100% DMSO	Test Substance ¹	Discard	E2 Testing Stock	Estrogen- free DMEM ²	Final Volume
1	-	4 μL of test substance solution from Section 10.2.4 step 1	-	4 μL	800 μL	808 μL
2	16 μL	4 μL of test substance solution from Section 10.2.4 step 1	-	4 μL	800 μL	808 μL
3	16 μL	4 μL from Tube #2	-	4 μL	800 μL	808 μL
4	16 μL	4 μL from Tube #3	-	4 μL	800 μL	808 μL
5	16 μL	4 μL from Tube #4	-	4 μL	800 μL	808 μL
6	16 μL	4 μL from Tube #5	-	4 μL	800 μL	808 μL
7	16 μL	4 μL from Tube #6	-	4 μL	800 μL	808 μL
8	16 μL	4 μL from Tube #7	-	4 μL	800 μL	808 μL
9	16 μL	4 μL from Tube #8	-	4 μL	800 μL	808 μL
10	16 μL	4 μL from Tube #9	-	4 μL	800 μL	808 μL
11	16 μL	4 μL from Tube #10	20 μL	4 μL	800 μL	808 μL

^TVortex tubes #2 through 10 before removing test substance/DMSO solution to place in the next tube in the series.

²Vortex all tubes to mix media, test substance, and E2.

13.0 GENERAL PROCEDURES FOR THE TESTING OF CODED SUBSTANCES

Range finder experiments are used to determine the concentrations of test substance to be used during comprehensive testing. Comprehensive testing experiments are used to determine whether a substance possesses ER antagonist activity in the LUMI-CELL® ER test method.

General procedures for range finder and comprehensive testing are nearly identical. For specific details (such as plate layout) of range finder testing see **Section 14.0**. For specific details of comprehensive testing, see **Section 15.0**.

13.1 Application of Reference Standard, Control and Test Substances

- 1. Remove the 96-well plates (from **Section 9.2.3 step 18)** from the incubator; inspect them using an inverted microscope. Only use plates in which the cells in all wells receive a score of 1 according to **Table 11-1**.
- 2. Remove medium by inverting the plate onto blotter paper. Gently tap plate against the bench surface to remove residual liquid trapped in the wells.

887		3.	Add 200 µL of medium, reference standard, control or test substance to each well
888			(see Sections 14.0 and 15.0 for specific plate layouts).
889		4.	Return plates to incubator (see Section 9.0 for details) for 19 to 24 hours to allow
890			maximal induction of luciferase activity in the cells.
891	13.1.1	Pre	eparation of Excel® Data Analysis Template For Range Finder Testing
892		1.	In Excel®, open a new "AntRFTemplate" and save it with the appropriate project
893			name as indicated in the NICEATM Style Guide.
894		2.	Fill out the table at the top of the "Raw Data" worksheet with information
895			regarding the Microplate reader used, Reading Direction, No. of Intervals, Tot.
896			Meas. Time/Well (s), etc. (note: this information can be permanently added to the
897			default template "AntRFTemplate" on a laboratory specific basis).
898		3.	Add the following information regarding the assay to the "Compound Tracking"
899			worksheet.
900			Plate # - Enter the experiment ID or plate number into cell E1
901			 Cell Lot # - Enter the passage or lot number of the cells used for this
902			experiment into cell B5
903			■ DMSO and Media Lot #'s – Enter the lot numbers for the DMSO and
904			Media in cells B6 and B7
905			■ Test Substance Code – Enter the test substance codes into cells C14 to
906			C19
907			 Name: Enter the experimenter name into cell G6
908			■ Date: Enter the experiment date in the format day\month\year into cell
909			G10
910			• Comments: - Enter any comments about the experiment in this box (e.g.,
911			plate contaminated)
912		4.	Enter the following substance testing information to the "List" worksheet:

913		■ Concentration – Type in the test substance concentration in µg/ml in
914		descending order.
915		 Any specific comments about the test substance or condition of the wells
916		should be entered into this sheet, in the comments section
917		 All of the remaining cells on the "List" worksheet should populate
918		automatically.
919		■ The "Template", "Compound Mixing" and "Visual Inspection"
920		worksheet should automatically populate with the information entered
921		into the "Compound Tracking" and "List" worksheet.
922		5. Save the newly named project file.
923		6. Print out either the "List" or "Template" worksheet for help with dosing the 96-
924		well plate. Sign and date the print out and store in study notebook.
925	13.1.2	Preparation of Excel® Data Analysis Template for Comprehensive Testing
926		1. In Excel®, open a new "AntCTTemplate" and save it with the appropriate project
927		name as indicated in the NICEATM Style Guide.
928		2. Fill out the table at the top of the "Raw Data" worksheet with information
929		regarding the Microplate reader used, Reading Direction, No. of Intervals, Tot.
930		Meas. Time/Well (s), etc. (note: this information can be permanently added to the
931		default template "AntCTTemplate" on a laboratory specific basis).
932		3. On the "Compound Tracking" worksheet, enter the following information:
933		 Plate # - Enter the experiment ID or plate number into cell E1
934		 Cell Lot # - Enter the passage or lot number of the cells used for this
935		experiment into cell C5
936		■ DMSO and Media Lot #'s – Enter the lot numbers for the DMSO and
937		Media in cells C6 and C7
938		■ Test Substance Code – Enter the test substance codes into cells C15 and
939		C16. Enter the test substance dilution into cells D15 and D16.

940			 Name: Enter the experimenter name into cell F6
941			■ Date: Enter the experiment date in the format day\month\year into cell
942			G10
943			• Comments: - Enter any comments about the experiment in this box (e.g.,
944			plate contaminated)
945		4.	Enter the following substance testing information to the "List" worksheet:
946			• Concentration – Type in the test substance concentration in μg/ml in
947			descending order.
948			 Any specific comments about the test substance or condition of the wells
949			should be entered into this sheet, in the comments section
950			 All of the remaining cells on the "List" worksheet should populate
951			automatically.
952			■ The "Template", "Compound Mixing" and "Visual Inspection"
953			worksheet should automatically populate with the information entered
954			into the "Compound Tracking" and "List" worksheet.
955		5.	Save the newly named project file.
956		6.	Print out either the "List" or "Template" worksheet for help with dosing the 96-
957			well plate. Sign and date the print out and store in study notebook.
958	13.2	Vis	ual Evaluation of Cell Viability
959		1.	19 to 24 hours after dosing the plate, remove the plate from the incubator and
960			remove the media from the wells by inverting the plate onto blotter paper. Gently
961			tap plate against the bench surface to remove residual liquid trapped in the wells.
962		2.	Use a repeat pipetter to add 50 μL 1X PBS to all wells. Immediately remove PBS
963			by inversion.
964		3.	Using an inverted microscope, inspect all of the wells used in the 96-well plate
965			and record the visual observations using the scores in Table 13-1 .
966			

Table 13-1 Visual Observation Scoring

Viability Score	Brief Description ¹
1	Normal Cell Morphology and Cell Density
2	Altered Cell Morphology and/or Small Gaps between Cells
3	Altered Cell Morphology and/or Large Gaps between Cells
4	Few (or no) Visible Cells
P	Wells containing precipitation are to be noted with "P"

¹Reference photomicrographs are provided in the LUMI-CELL® ER Validation Study "Visual Observation Cell Viability Manual."

969

970

971

972

973

974

975

976

977

978

979

980

981

982

983

967

968

966

13.3 Lysis of Cells for LUMI-CELL® ER

- 1. Apply the reflective white backing tape to the bottom of the 96-well plate (this will increase the effectiveness of the luminometer).
- 2. Add 30µL 1X lysis reagent to the assay wells and place the 96-well plate on an orbital shaker for one minute.
- 3. Remove plate from shaker and measure luminescence (as described in **Section 13.4**).

13.4 Measurement of Luminescence

Luminescence is measured in the range of 300 to 650 nm, using an injecting luminometer and with software that controls the injection volume and measurement interval. Light emission from each well is expressed as relative light units (RLU) per well. The luminometer output is saved as raw data in an Excel® spread sheet. A hard copy of the luminometer raw data should be signed, dated and stored in the study notebook.

13.5 Data Analysis

- LUMI-CELL® ER uses an Excel® spreadsheet to collect and adjust the RLU values obtained from the luminometer and a GraphPad Prism® template to analyze and graph data. Plate reduction is calculated using unadjusted RLU values.
- The Excel® spreadsheet subtracts background luminescence (average DMSO solvent control RLU value) from test substance, reference standard and control RLU values. Test substance, reference standard, and control RLU values are then adjusted relative to the highest Ral/E2

990	reference	standard RLU value, which is set to 10,000. After adjustment, values are transferred to
991	GraphPad	Prism® for data analysis and graphing.
992	13.5.1	Collection and Adjustment of Luminometer Data for Range Finder Testing
993	The follow	ving steps describe the procedures required to populate the Excel® spreadsheet that has
994	been confi	igured to collect and adjust the RLU values obtained from the luminometer.
995		1. Open the raw data file and the corresponding experimental Excel® spreadsheet
996		from Section 13.1.1.
997		2. Copy the raw data using the Excel® copy function, then paste the copied data into
998		cell B19 of the "RAW DATA" tab in the experimental Excel® spreadsheet using
999		the Paste Special - Values command. This position corresponds to position A1 in
1000		the table labeled Table 1 in this tab.
1001		3. Examine the DMSO data in Table 1 of the Excel® spreadsheet to determine
1002		whether there are any potential outliers. See Section 13.5.3 for further explanation
1003		of outlier determinations.
1004		4. If an outlier is identified, perform the following steps to remove the outlier from
1005		calculations:
1006		 correct the equation used to calculate DMSO background in Table 1
1007		[e.g., if outlier is located in cell F26, adjust the calculation in cell H40 to
1008		read = $AVERAGE(E26,G26)$]
1009		 then correct the equation used to calculate the average DMSO value in
1010		Table 2 [e.g., following the above example, adjust cell M42 to read
1011		=AVERAGE(E38,G38)]
1012		 then correct the equation used to calculate the standard deviation of the
1013		DMSO value in Table 2 [e.g., following the above example, adjust cell
1014		M43 to read =STDEV(E38,G38)]
1015		5. Excel® will automatically subtract the background (the average DMSO control
1016		value) from all of the RLU values in Table 1 and populate Table 2 with these
1017		adjusted values.

10181019	6. To calculate plate reduction, identify the cell containing the Ral/E2a replicate in Table 1, plate row H that has the lowest RLU value (i.e., cell B26, C26, or D26).
1020 1021	7. Identify the cell containing the Ral/E2a replicate in Table 1, plate row H that has the highest RLU value (i.e., cell B26, C26, or D26).
1022 1023	8. Click into cell D14 and enter the cell number from Section 13.5.1 step 7 into the numerator and the cell number from step 6 into the denominator.
1024 1025	9. Identify the cell containing the Ral/E2b replicate in Table 1, plate row H that has the lowest RLU value (i.e., cell K26, L26, or M26).
1026 1027	10. Identify the cell containing the Ral/E2b replicate in Table 1, plate row H that has the highest RLU value (i.e., cell K26, L26, or M26).
1028 1029	11. Click into cell E14 and enter the cell number from Section 13.5.1 step 10 into the numerator and the cell number from step 9 into the denominator.
1030	12. Click on the "ER Antagonist Report" worksheet.
1031 1032 1033	13. The data for the Ral/E2 reference standard, DMSO, and E2, replicates populate the left portion (columns A-F) of the spreadsheet. The data is automatically placed into an Excel [®] graph.
1034 1035 1036 1037	14. To set the highest RLU value for the reference standard to 10,000 RLU, go to cell C2 of "ER Antagonist Report" worksheet and check the formula contained within that cell. The divisor should be the cell number of the cell containing the highest averaged Ral/E2 RLU value (column A).
1038 1039 1040	15. Open the "Visual Observation Scoring" worksheet. Enter the visual observation scores for each well on the 96-well plate. This data will be linked to the "ER Antagonist Report" worksheet.
1041 1042	16. After the testing results have been evaluated and reviewed for quality control, enter the following information into the Compound Tracking worksheet:
1043 1044	 Enter pass/fail results for plate reference standard and control parameters into the Plate Pass/Fail Table

1045 1046		 Enter information from the testing of coded substances into the Testing Results Table
1047 1048		 Reviewer Name – Enter the name of the person who Reviewed\QC'ed the data into cell A34
1049		■ Date – Enter the date on which the data was reviewed into cell D34
1050 1051	13.5.2	Collection and Adjustment of Luminometer Data for Comprehensive Testing
1052 1053 1054 1055		ring steps describe the procedures required to populate the Excel [®] spreadsheet that has gured to collect and adjust the RLU values obtained from the luminometer. 1. Open the raw data file and the corresponding experimental Excel [®] spreadsheet from Section 13.1.2 .
1056 1057 1058 1059		2. Copy the raw data using the Excel® copy function, then paste the copied data into cell B14 of the "RAW DATA" tab in the experimental Excel® spreadsheet using the Paste Special – Values command. This position corresponds to position A1 in the table labeled Table 1 in this tab.
1060 1061 1062		3. Examine the DMSO data in Table 1 of the Excel® spreadsheet to determine whether there are any potential outliers. See Section 13.5.3 for further explanation of outlier determinations.
1063 1064		4. If an outlier is identified, perform the following steps to remove the outlier from calculations:
1065 1066 1067		 correct the equation used to calculate DMSO background in Table 1[e.g., if outlier is located in cell M14, adjust the calculation in cell H40 to read =AVERAGE(M15:M17)]
1068 1069 1070		 then correct the equation used to calculate the average DMSO value in Table 2 [e.g., following the above example, adjust cell M35 to read =AVERAGE(M25:M27)]

1071		 then correct the equation used to calculate the standard deviation of the
1072		DMSO value in Table 2 [e.g., following the above example, adjust cell
1073		M36 to read =STDEV(M25:M27)]
1074	5.	Excel® will automatically subtract the background (the average DMSO control
1075		value) from all of the RLU values in Table 1 and populate Table 2 with these
1076		adjusted values.
1077	6.	To calculate plate reduction, identify the cell containing the Ral/E2 replicate in
1078		plate row G that has the lowest RLU value.
1079	7.	Identify the cell containing the Ral/E2 replicate in plate row G that has the highest
1080		RLU value.
1081	8.	Click into cell D14 and enter the cell number from Section 13.5.2 step 7 into the
1082		numerator and the cell number from step 6 into the denominator.
1083	9.	Identify the cell containing the Ral/E2 replicate in plate row H that has the lowest
1084		RLU value.
1085	10.	Identify the cell containing the Ral/E2 replicate in plate row H that has the highest
1086		RLU value.
1087	11.	Click into cell E14 and enter the cell number from Section 13.5.2 step 10 into the
1088		numerator and the cell number from step 9 into the denominator.
1089	12.	Click on the "ER Antagonist Report" worksheet.
1090	13.	The data for the Ral/E2 reference standard, DMSO, E2, and Flavone/E2 replicates
1091		populate the left portion (columns A-E) of the spreadsheet. The data is
1092		automatically placed into an Excel® graph.
1093	14.	To set the highest RLU value for the reference standard to 10,000 RLU, go to cell
1094		D2 of "ER Antagonist Report" worksheet and check the formula contained within
1095		that cell. The divisor should be the cell number of the cell containing the highest
1096		averaged Ral/E2 RLU value (column A).

1097	15. Open the "Visual Observation Scoring" worksheet. Enter the visual observation
1098	scores for each well on the 96-well plate. This data will be linked to the "ER
1099	Antagonist Report" worksheet.
1100	16. Copy the data into GraphPad Prism® for the calculation of IC ₅₀ values and to
1101	graph experimental results as indicated in the NICEATM Prism® Users Guide.
1102	17. After the testing results have been evaluated and reviewed for quality control,
1103	enter the following information into the Compound Tracking worksheet:
1104	 Enter pass/fail results for plate reference standard and control parameters
1105	into the Plate Pass/Fail Table
1106	 Enter information from the testing of coded substances into the Testing
1107	Results Table
1108	■ Reviewer Name – Enter the name of the person who Reviewed\QC'ed the
1109	data into cell A34
1110	■ Date – Enter the date on which the data was reviewed into cell D32
1111	13.5.3 <u>Determination of Outliers</u>
1112	The Study Director will use good statistical judgment for determining "unusable" wells that will
1113	be excluded from the data analysis and will provide an explanation in the study notebook for any
1114	excluded data. This judgment for data acceptance will include Q-test analysis.
1115	The formula for the Q test is:
1116	Outlier – Nearest Neighbor
1110	Range (Highest – Lowest)
1117	where the outlier is the value proposed for exclusion, the nearest neighbor is the value closest to
1118	the outlier, and the range is the range of the three values (Q values for samples sizes from 3 to 10
1119	are provided in Table 13-2). For example, if the value of this ratio is greater than 0.94 (the Q
1120	value for the 90% confidence interval for a sample size of three) or 0.76 (the Q value for the 90%
1121	confidence interval for a sample size of four), the outlier may be excluded from data analysis.
1122	

1122 Table 13-2 O Test Values

Number Of Observations	Q Value
2	-
3	0.94
4	0.76
5	0.64
6	0.56
7	0.51
8	0.47
9	0.44
10	0.41

1123

1124

1125

1126

1129

1130

1131

1132

1133

1134

1135

1136

For E2 reference standard replicates (sample size of two), any adjusted RLU value for a replicate at a given concentration of E2 is considered and outlier if its value is more than 20% above or below the adjusted RLU value for that concentration in the historical database.


1127 13.5.4 <u>Acceptance Criteria</u>

1128 13.5.4.1 Range Finder Testing

- Acceptance or rejection of a range finder test is based on reference standard and solvent control results from each experiment conducted on a 96-well plate.
 - Reduction: Plate reduction, as measured by dividing the averaged highest Ral/E2 reference standard RLU value by the averaged DMSO control RLU value, must be greater than three-fold.
 - DMSO control results: DMSO control RLU values must be within 2.5 times the standard deviation of the historical solvent control mean RLU value (see **Section 16.5**).
- An experiment that fails either acceptance criterion will be discarded and repeated.
- 1138 13.5.4.2 Comprehensive Testing
- Acceptance or rejection of a test is based on evaluation of reference standard and control results from each experiment conducted on a 96-well plate. Results are compared to quality controls (QC) for these parameters derived from the historical database (see **Section 16.5**), which are summarized below.

1143	•	Reduction: Plate reduction, as measured by dividing the averaged highest Ral/E2
1144		reference standard RLU value by the averaged lowest Ral/E2 control RLU value,
1145		must be greater than three-fold.
1146	•	DMSO control results: DMSO control RLU values must be within 2.5 times the
1147		standard deviation of the historical solvent control mean RLU value (see Section
1148		16.5).
1149	•	Reference standard results: The Ral\E2 reference standard concentration-response
1150		curve should be sigmoidal in shape and have at least three values within the linear
1151		portion of the concentration-response curve.
1152	•	E2 control results: E2 control RLU values must be within 2.5 times the standard
1153		deviation of the historical E2 control mean RLU value.
1154	•	Positive control results: Flavone/E2 control RLU values must be less than the E2
1155		control mean minus three times the standard deviation from the E2 control mean.
1156	An experime	nt that fails any single acceptance criterion will be discarded and repeated.
1157	14.0 RA	ANGE FINDER TESTING
1158	Antagonist ra	ange finding for coded substances consists of seven point, 1:10 serial dilutions tested
1159	in duplicate v	wells of the 96-well plate. Figure 14-1 contains a template for the plate layout used
1160	in antagonist	range finder testing.
1161		

1161 Figure 14-1 Antagonist Range Finder Plate Layout



- Three Point Ral/E2 Reference Standard
- **DMSO** (Solvent Control)
- Range Finder for Sample #1
- Range Finder for Sample #2
- Range Finder for Sample #3
- Range Finder for Sample #4
- Range Finder for Sample #5
- Range Finder for Sample #6
- **E2** Control


1163 Evaluate whether range finder experiments have met acceptance criteria (see Section 13.6.3). 1164 To determine starting concentrations for comprehensive testing use the following criteria: 1165 If results in the range finder test suggest that the test substance is negative for 1166 antagonist activity (i.e., if there are no points on the test substance concentration 1167 curve that are less than the mean minus three times the standard deviation of the 1168 E2 control, see **Figure 14-2**), comprehensive testing will be conducted using an 1169 11-point 1:2 serial dilution using the maximum soluble concentration of test substance as the with the limit dose as the starting concentration. 1170 1171 If results in the range finder test suggest that the test substance is negative for 1172 agonist activity (i.e., if there are no points on the test substance concentration 1173 curve that are greater than the mean plus three times the standard deviation of the 1174 DMSO control), and the higher concentrations in the range finder are cytotoxic, 1175 comprehensive testing will be conducted using an 11 point 1:2 serial dilution with 1176 the lowest cytotoxic concentration as the starting concentration (see **Figure 14-3**). 1177 If results in the range finder test suggest that the test substance is positive for 1178 antagonist activity (i.e., if there are points on the test substance concentration 1179 curve that are less than the mean minus three times the standard deviation of the 1180 E2 control), the top concentration to be used for the 11-point dilution scheme in 1181 comprehensive testing should be one of the following: 1182 The concentration giving the lowest adjusted RLU value in the range 1183 finder 1184 The maximum soluble concentration (See Figure 14-2) 1185 The lowest cytotoxic concentration (See Figure 14-3 for a related 1186 example). 1187 The 11-point dilution scheme will be based on either a 1:2 or 1:5 serial or dilution 1188 according to the following criteria: 1189 An 11-point 1:2 serial dilution should be used if the resulting 1190 concentration range (note: an 11-point 1:2 serial dilution will cover a

range of concentrations over approximately three orders of magnitude

 [three logs]) will encompass the full range of responses based on the concentration response curve generated in the range finder test (see **Figure 14-4**).


- If the concentration range that would be generated with the 1:2 serial dilution will not encompass the full range of responses based on the concentration response curve in the range finder test (see Figure 14-5), an 11-point 1:5 serial dilution should be used instead.
- If a substance exhibits a biphasic concentration response curve in the range finder test (see **Figure 14-6**), both phases should also be resolved in comprehensive testing. In this case, two peaks could potentially be used to identify the top concentration to be used for the 11-point dilution scheme in comprehensive testing. In order to resolve both curves, the top concentration should be based on the peak associated with the higher concentration and the top dose one log concentration higher than the concentration giving the lowest adjusted RLU value in the range finder. An 11-point 1:5 serial dilution should be used.

Figure 14-2 Antagonist Range Finder (example 1)



The solid horizontal line represents the mean minus three times the standard deviation of the E2 control.

1210 Figure 14-3 Antagonist Range Finder (example 2)




The solid horizontal line represents the mean minus three times the standard deviation of the E2 control.

Figure 14-4 Antagonist Range Finder (example 3)

1211


1213

1214



The solid horizontal line represents the mean minus three times the standard deviation of the E2 control.


1216 Figure 14-5 Antagonist Range Finder (example 4)



12171218

The solid horizontal line represents the mean minus three times the standard deviation of the E2 control.

1219 Figure 14-6 Antagonist Range Finder (example 5)



1220 1221

The solid horizontal line represents the mean minus three times the standard deviation of the E2 control.

point, 1:2 serial dilutions,

1222	
1223	15.0 COMPREHENSIVE TESTING
1224	Antagonist comprehensive testing for coded substances consists of 11 point, 1:2 serial dilution
1225	with each concentration tested in triplicate wells of the 96-well plate. Figure 15-1 contains a

template for the plate layout to be used in antagonist comprehensive testing.

1227

1226

1228

Antagonist Comprehensive Test Plate Layout Figure 15-1

Evaluate whether comprehensive experiments have met acceptance criteria (see **Section 13.6.3**) and graph the data as described in the NICEATM Prism® users guide.

- If the substance has been tested up to the limit dose or the maximum soluble dose without causing a significant decrease in cell viability, and there are no points on the concentration curve that are less than the mean minus three times the standard deviation of the E2 control, the substance is considered negative for antagonism.
- If the substance has been tested up to the limit dose and there are points on the concentration curve that are less than the mean minus three times the standard deviation of the E2 control, but cell viability has a visual inspection score of 2 or greater, at all points falling below the E2 line, the substance is considered negative for antagonism.
- If there are points on the test substance concentration curve that are less than the mean minus three times the standard deviation of the E2 control that do not cause a visual inspection score of 2 or greater, the substance is positive for antagonism.
 - Points in the test substance concentration curve that cause a visual inspection score of 2 or greater, are not included in data analyses.

16.0 COMPILATION OF THE HISTORICAL QUALITY CONTROL DATABASE

Historical databases are maintained in order to ensure that the assay is functioning properly.

Historical databases are compiled using Excel® spreadsheets and are separate from the

spreadsheets used to collect the data for individual test plates. Reference standard and control

data is used to develop and maintain the historical database and are used as quality controls to

determine acceptance of individual test plates.

The sources of data needed to compile the historical database for the E2 control and flavone/E2 control values are the experiment specific Excel[®] data collection and analysis spreadsheets (see Section 13.5.2) used for LUMI-CELL[®] ER antagonist testing. The sources of the data needed to compile the historical database for the DMSO control are the experiment specific Excel[®] data collection and analysis spreadsheets used for LUMI-CELL[®] ER antagonist and agonist testing

(see Section 13.5.2 of the LUMI-CELL® ER antagonist protocol and Section 11.5.2 in the 1285 1286 LUMI-CELL® ER agonist protocol). 1287 16.1 E2 Control Open the LUMI-CELL® ER antagonist specific historical database Excel® spreadsheet 1288 (LUMI AgandAntQC.xls) and save under a new name using the Excel® "Save As" function. 1289 adding the laboratory designator to the file name (e.g., for Laboratory H, the new name would be 1290 1291 HLUMI AgandAntQC.xls). Open the E2 Control worksheet and enter the date and experiment 1292 name into worksheet columns A and B respectively. Enter the experimental mean adjusted E2 1293 control value (from cell D37 in the ER Antagonist Report worksheet of the Excel® data 1294 collection and analysis spreadsheet) into the Antagonist E2 control worksheet, column C. 1295 Acceptance or rejection of plate E2 control data for comprehensive testing is based on whether 1296 the mean plate E2 RLU value falls within 2.5 times the standard deviation of the E2 value in the 1297 historical database (columns G and H in the E2 Control worksheet). 1298 16.2 **DMSO** Open the combined agonist and antagonist LUMI-CELL® ER historical database Excel® 1299 spreadsheet (LUMI AgandAntQC.xls) and save under a new name using the Excel® "Save As" 1300 1301 function, adding the laboratory designator to the file name (e.g., for Laboratory H, the new name 1302 would be HLUMI AgandAntQC.xls). Enter the date and experiment name into worksheet 1303 columns A and B respectively. Enter the experimental mean DMSO control value (from cell H37 in the RAW DATA worksheet of the agonist and antagonist Excel® data collection and analysis 1304 1305 spreadsheet) into worksheet column C. Acceptance or rejection of the plate DMSO control data 1306 for range finding and comprehensive testing is based on whether the mean plate DMSO RLU 1307 value falls within 2.5 times the standard deviation of the DMSO value in the historical database 1308 (columns G and H in the DMSO worksheet). 1309 1310 17.0 **QUALITY TESTING OF MATERIALS** 1311 All information pertaining to the preparation and testing of media, media supplements, and other 1312 materials should be recorded in the Study Notebook.

1313	17.1	Tis	sue Culture Media
1314	Each lot of	of tis	sue culture medium must be tested in a single growth flask of cells before use in
1315	ongoing t	issue	e culture or experimentation (note: each bottle within a given lot of
1316	Charcoal	/Dex	tran treated FBS must be tested separately).
1317		1.	Every new lot of media (RPMI and DMEM) and media components (FBS,
1318			Charcoal/Dextran treated FBS, and L-glutamine) must first be tested on the
1319			LUMI-CELL® ER assay prior to being used in any GLP acceptable assays.
1320		2.	Add 4 μL of DMSO (previously tested) into four separate 13 mm tubes.
1321		3.	Add 400 μL media (to be tested) to 13 mm tube.
1322		4.	Dose an experimental plate as in Section 12.0, treating the media being tested as a
1323			test substance.
1324		5.	Analyze 96-well plate as described in Section 12.0 , comparing the data from the
1325			DMSO controls made using previously tested tissue culture media to the new
1326			media being tested.
1327		6.	Use the agonist historical database to determine if the new media with DMSO lies
1328			within 2.5 standard deviations of the mean for the media. If the RLU values for
1329			the new media with DMSO lie within 2.5 standard deviations of the DMSO mean
1330			from the historical database, the new lot of media is acceptable. If the RLU values
1331			for the new media with DMSO do not lie within 2.5 standard deviations of the
1332			DMSO mean from the historical database, the new lot may not be used in the
1333			assay.
1334		7.	Note date and lot number in study notebook.
1335		8.	If the new bottle passes quality testing as described in Section 15.1 step 6 , apply
1336			the media to a single flask cells and observe the cells growth and morphology
1337			over the following 2 to 3 days. If there is no change in growth or morphology, the
1338			new media is acceptable for use.

1339	17.2	G4	18
1340		1.	New lots of G418 must first be tested on the LUMI-CELL® ER assay prior to
1341			being used in any GLP acceptable assays.
1342 1343		2.	Add 220 μL of G418 (previously tested) to a single flask containing cells growing in RPMI.
1344 1345		3.	Add 220 μL of G418 (to be tested) to a different flask containing cells growing in RPMI.
1346 1347 1348		4.	Observe cellular growth and morphology in both tissue culture flasks over a 48 to 72 hour period. If there are no differences in observed growth rate and morphology between the two flasks, the new G418 lot is acceptable.
1349 1350		5.	If cellular growth is decreased, or the cells exhibit abnormal morphology, the new lot of G418 is not acceptable.
1351		6.	Note date and lot number in study book.
1352	17.3	DM	ISO
1353 1354		1.	Every new bottle of DMSO must be tested on the LUMI-CELL® ER assay prior to use in any GLP acceptable assays.
1355		2.	Add 4 μL of DMSO (to be tested) into four separate 13 mm tubes.
1356		3.	Add 400 μL media (previously tested) the same tubes.
1357 1358		4.	Dose an experimental plate as in Section 15.0 , treating the media being tested as a test substance.
1359 1360 1361		5.	Analyze 96-well plate as described in Section 15.0 , comparing the data from the DMSO controls made using previously tested tissue culture media to the new media being tested.
1362 1363 1364		6.	Use the agonist historical database to determine if media with new DMSO lies within 2.5 standard deviations of the DMSO mean from historical database. If the RLU values for the media with new DMSO lie within 2.5 standard deviations of the DMSO mean from the historical database, the new lot of DMSO is acceptable.
1000			THE LAVISO HEAR HORE THE HISTORICAL GALADASE. THE NEW TOLOL DIVISO IS ACCEPTABLE

1366			If the RLU values for media with new DMSO do not lie within 2.5 standard
1367			deviations of the DMSO mean from historical database, the new lot may not be
1368			used in the assay.
1369		7.	Note the date, lot number, and bottle number in study book.
1370		8.	If no DMSO has been previously tested, test several bottles as described in
1371			Section 15.3, and determine whether any of the bottles of DMSO have a higher
1372			average RLU than the other bottle(s) tested. Use the DMSO with the lowest
1373			average RLU for official experiments.
1374	17.4	Pla	astic Tissue Culture Materials
1375		1.	Grow one set of cells, plate them for experiments on plastic ware from the new lot
1376			and one set of cells in the plastic ware from a previous lot, and dose them with E2
1377			reference standard and controls.
1378		2.	Perform the LUMI-CELL® ER experiment with both sets of cells.
1379		3.	If all of the analysis falls within acceptable QC criteria, then the new
1380			manufacturer's products may be used.

1383	Eli Lilly and Company and National Institutes of Health Chemical Genomics Center. 2005. Assay Guidance Manual Version 4.1. Bethesda, MD: National Institutes of Health. Available: http://www.ncgc.nih.gov/guidance/manual_toc.html [accessed 05 September 2006]
1386	ICCVAM. 2001. Guidance Document on Using <i>In Vitro</i> Data to Estimate <i>In Vivo</i> Starting Doses for Acute Toxicity. NIH Pub. No. 01-4500. Research Triangle Park, NC: National Institute of
	Environmental Health Sciences. Available: http://iccvam.niehs.nih.gov/methods/invidocs/guidance/iv_guide.pdf [accessed 31 August 2006]